How mRNA Vaccines Could Aid Cancer Treatment
mRNA, or messenger RNA, provides temporary instructions that help cells produce specific proteins. While best known for teaching the immune system to recognize the SARS-CoV-2 virus, researchers are now exploring how mRNA vaccines might help the body spot and attack cancer cells.
The American Cancer Society (ACS) notes that mRNA vaccines can be manufactured quickly, and—unlike traditional cancer vaccines—can be personalized to target a patient’s unique tumor proteins or designed in standardized forms for broader use.
Earlier work focused on tailor-made mRNA cancer vaccines, but these can be time-consuming to produce. The new study found that even non-cancer mRNA vaccines, such as the COVID-19 vaccine, can activate antiviral pathways that help immune therapies work better.
Why Immune Checkpoint Inhibitors Need Help
ICIs work by blocking proteins—such as PD-1 or PD-L1—that cancers use to hide from the immune system. While the drugs have extended survival for some patients, “cold” tumors often remain resistant because they lack pre-existing immune activity.
Lead author Adam J. Grippin, M.D., Ph.D., a radiation oncology resident at The University of Texas MD Anderson Cancer Center, explained that the research team wanted to see whether mRNA vaccines could “wake up” the immune system enough to make resistant tumors more responsive to ICIs.
What the Researchers Did
The study combined multiple approaches:
- Retrospective patient data from MD Anderson for people with advanced non-small cell lung cancer (NSCLC), melanoma and other cancers
- Immune monitoring in healthy volunteers after COVID-19 mRNA vaccination
- Preclinical mouse models treated with mRNA vaccines alone or alongside ICIs
Across all components, researchers measured immune activity using tools such as flow cytometry, ELISA and immunofluorescence. All human and animal studies received institutional review board approval.
Key Findings in Patients
For patients with NSCLC and metastatic melanoma, vaccination within 100 days of ICI treatment was associated with stronger outcomes:
NSCLC (MD Anderson cohort):
- Median overall survival: 37.3 months (vaccinated) vs 20.6 months (unvaccinated)
- Three-year OS: 55.7% vs 30.8%
- Adjusted hazard ratio: 0.51 (95% CI 0.37–0.71, p < 0.0001)
- Stage III and IV patients also saw significant benefit
Metastatic melanoma:
- 36-month OS: 67.6% vs 44.1%
- Median progression-free survival: 10.3 months vs 4.0 months
- HR: 0.37 (95% CI 0.18–0.74, p = 0.0048)
Researchers also observed that vaccinated patients tended to have higher PD-L1 levels in tumor tissue—an average tumor proportion score of 31% compared with 22%–25% among unvaccinated patients.
Findings in Healthy Volunteers and Mice
Healthy volunteers showed a dramatic but temporary surge in immune activity following vaccination, including:
- A 280-fold increase in IFN-α
- Elevated levels of activated T cells and natural killer cells
These immune signatures peaked around 24 hours post-vaccination and normalised within a week.
In mice, tumors responded more strongly to ICIs when paired with mRNA vaccination, suggesting that the vaccines helped immune cells infiltrate the tumor microenvironment.
Potential Implications and Remaining Questions
The results indicate that common, low-cost mRNA vaccines may help ICIs work better—even though the vaccines do not directly target cancer cells. This could offer a more accessible complement to personalized mRNA cancer vaccines.
However, researchers noted several limitations. The study examined only a single vaccine type and did not directly compare its effects with personalized cancer vaccines. Questions remain about optimal timing, long-term outcomes and whether similar effects occur with other ready-to-use RNA technologies.
What Comes Next
The authors suggest exploring additional off-the-shelf RNA therapies to strengthen the immune system’s anti-tumor activity. They also propose further studies to understand whether routine vaccinations could play a role in improving cancer treatment responses more broadly.